-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Bristol-Myers Squibb Company's Income Statement
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$46.39 B | $46.16 B | $45.01 B | $48.30 B | $48.19 B |
| Cost of Revenue |
|
$19.62 B | $19.67 B | $19.65 B | $20.87 B | $15.59 B |
| Gross Profit |
|
$26.76 B | $26.49 B | $25.36 B | $27.43 B | $32.60 B |
| Research & Development |
|
$9.53 B | $9.41 B | $9.21 B | $9.78 B | $9.61 B |
| Selling,General & Administrative |
|
$7.69 B | $7.81 B | $7.68 B | $7.87 B | $7.24 B |
| Operating Expense |
|
$17.22 B | $17.22 B | $16.89 B | $17.77 B | $19.91 B |
| Operating Income |
|
$9.54 B | $9.27 B | $8.47 B | $9.66 B | $12.70 B |
| Net Income |
|
$6.99 B | $6.33 B | $8.03 B | -$8.95 B | $7.05 B |
Bristol-Myers Squibb Company's Balance Sheet
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$17.22 B | $9.25 B | $12.28 B | $10.86 B | $10.67 B |
| Inventories |
|
$2.10 B | $2.34 B | $2.66 B | $2.56 B | $2.69 B |
| Total Current Assets |
|
$33.26 B | $27.27 B | $31.77 B | $29.78 B | $29.39 B |
| Property,Plant and Equipment |
|
$6.97 B | $7.48 B | $8.04 B | $8.36 B | $9.13 B |
| Goodwill |
|
$20.50 B | $21.15 B | $21.17 B | $21.72 B | $21.75 B |
| Total Assets |
|
$109.31 B | $96.82 B | $95.16 B | $92.60 B | $90.04 B |
| Total Liabilities |
|
$73.31 B | $65.70 B | $65.67 B | $76.22 B | $71.53 B |
| Retained Earnings |
|
$23.82 B | $25.50 B | $28.77 B | $14.91 B | $16.90 B |
| Total Shareholder Equity |
|
$35.95 B | $31.06 B | $29.43 B | $16.34 B | $18.47 B |
| Common Stock |
|
$292.00 M | $292.00 M | $292.00 M | $292.00 M | $292.00 M |
Bristol-Myers Squibb Company's Cash flow
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$10.69 B | $10.28 B | $9.76 B | $9.60 B | $4.01 B |
| Dividends Payout |
|
-$4.40 B | -$4.63 B | -$4.74 B | -$4.86 B | -$5.05 B |
| Capital Expenditures (Capex) |
|
-$973.00 M | -$1.12 B | -$1.21 B | -$1.25 B | -$1.31 B |
| Free Cash Flow (FCF) |
|
$15.23 B | $11.95 B | $12.65 B | $13.94 B | $12.85 B |
Bristol-Myers Squibb Company's Profitability
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$26.76 B | $26.49 B | $25.36 B | $27.43 B | $32.60 B |
| Gross Profit Margin (%) |
|
57.69% | 57.39% | 56.34% | 56.80% | 67.65% |
| Operating Income |
|
$9.54 B | $9.27 B | $8.47 B | $9.66 B | $12.70 B |
| Operating Income Margin (%) |
|
20.57% | 20.08% | 18.82% | 20.00% | 26.34% |
| Net Income |
|
$6.99 B | $6.33 B | $8.03 B | -$8.95 B | $7.05 B |
| Net Income Margin (%) |
|
15.08% | 13.71% | 17.83% | -18.53% | 14.63% |
| EBITDA |
|
$20.12 B | $19.22 B | $19.37 B | $3.17 B | $14.55 B |
| EBITDA Margin (%) |
|
43.37% | 41.64% | 43.03% | 6.56% | 30.18% |
Bristol-Myers Squibb Company's Ratios
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
19.46% | 20.37% | 27.27% | -54.78% | - |
| Return on Assets (ROA) |
|
6.40% | 6.53% | 8.43% | -9.66% | - |
| Debt to Equity |
|
126.85% | 131.09% | 140.89% | 313.44% | 255.18% |
| Debt to total asset |
|
41.71% | 42.05% | 43.57% | 55.29% | 52.35% |
| Enterprise value to revenue |
|
3.67 | 4.00 | 3.03 | 3.22 | 0.00 |
| Enterprise value to EBITDA |
|
8.45 | 9.62 | 7.03 | 49.08 | 0.00 |
| Enterprise value |
|
$170.10 B | $184.85 B | $136.16 B | $155.50 B | - |
| Tax Rate (%) |
|
13.39% | 17.74% | 4.74% | -6.61% | 24.36% |
Frequently Asked Questions
